Aronora

Catch us in Miami Beach for the inaugural Biotechnology Innovation Organization Investment and Growth Summit! Reach out to learn more on our groundbreaking cardio-hematology programs. We look forward to meeting old friends and new alike!

Our team had a terrific time presenting new data on AB002 at #ISC26! AB002 is the only thrombolytic in development for universal treatment of acute ischemic stroke (AIS). We were delighted to see KOL enthusiasm on the potential for AB002 to expand the treatment window and maximize patient eligibility for time-sensitive therapeutic intervention. Thank you to the #ISC26 organizers for an energizing program and we look forward to advancing AB002 through its next phase of clinical development this year!

We’re excited to start the new year by announcing the expansion of our leadership team! Aronora has named Grace Colón as chair of the board of directors, John Glasspool as board director, and Lekhan Shivashankar as chief of staff. Read our press release here: https://lnkd.in/e6j2UHGa

Aronora is proud to share that we presented new data on AB023 and AB062 at #ASH25.   AB023 is a first-in-class, Factor XI (FXI) inhibitor designed to bind the Apple 2 (A2) domain of FXI. This differentiated mechanism of action selectively inhibits Factor XII–mediated contact activation of FXI, while preserving thrombin-mediated FXI activation that supports fully functional hemostasis.   AB062 is a first-in-class, antisense oligonucleotide designed to inhibit hepatic production of thrombopoietin – a key regulator of platelet production whose signaling pathway is aberrantly activated in myeloproliferative neoplasms like essential thrombocythemia (ET).   We’re excited to hear KOLs echo our belief in the potential for Aronora's first-in-class programs to better serve patient communities at risk for life-threatening thrombosis.   Thank you to the #ASH25 organizers for an engaging program and we look forward to a productive year ahead!

Aronora will be at #ASH25!    We look forward to presenting new data on AB023 and AB062, while connecting with peers on ways to solve the challenges cardio-hematologic patients face today.   We hope to see you there!

Aronora is proud to share that our collaborative preclinical research on AB023 was presented at the American Heart Association’s 2025 Scientific Sessions. Our partners at KU Leuven, Tom Langenaeken, MD, and Lennart Vanglabeke, presented new data exploring the therapeutic potential of AB023 in a porcine model of mechanical valve thrombosis. AB023 is a novel Factor XI (FXI) inhibitor designed to bind the Apple 2 (A2) domain of FXI. This differentiated mechanism of action selectively inhibits Factor XII–mediated contact activation of FXI, while preserving thrombin-mediated FXI activation that supports fully functional hemostasis. Balancing efficacy and safety is critical when prescribing blood thinners to patients at risk of life-threatening thrombosis — especially individuals with medical devices such as mechanical heart valves. We extend our gratitude to our collaborators at KU Leuven for their pioneering work and continued partnership in reimagining the future of anticoagulation. Together, we are advancing AB023 as a highly differentiated, patient-centric FXI therapy tailored to thrombotic communities worldwide. #Thrombosis #FactorXI #AHA25

Aronora is proud to share that our collaborative preclinical research on AB062 was awarded Best Overall Abstract at the 17th International Congress on Myeloproliferative Neoplasms (MPNs).   The data was presented by our partners at UNC Chapel Hill, Brandi Reeves, MD and Karnsasin Seanoon, PhD, who investigated the therapeutic potential of AB062 in a murine model of MPN.   AB062 is a novel antisense oligonucleotide designed to inhibit hepatic production of thrombopoietin – a key regulator of platelet production whose signaling pathway is aberrantly activated in essential thrombocythemia (ET). ET is a chronic MPN that increases lifetime risk for thrombosis, bleeding, and malignant transformation into other MPNs.   This year, our conversations with KOLs underscored the persistent unmet need for innovative treatments that go beyond cytoreduction to address the underlying biological driver of ET.   We’re grateful to the MPN research community and our collaborators at the University of North Carolina at Chapel Hill, The Johns Hopkins University, and Ionis Pharmaceuticals, Inc. for their continued support.   Together, we’re advancing AB062 as a potential first-in-class, disease-modifying therapy for patients living with ET.   #EssentialThrombocythemia #PolycythemiaVera #Myelofibrosis #MPN